



**Table 1.** Some typical experimental conditions.<sup>12</sup>

Series	Starting Materials (mmol)				T (°C)	Reaction Time (h)	Product Number [Distribution Data]		
	1a	1b	1c	BrAd			2	3	4
a	20	-	-	10	120	4	100	-	-
a	20	-	-	10	230	4	13	86	1
a	10	-	-	20	230	1	14	37	49
b	-	10	-	10	230	4	75 <sup>a</sup>	25	-
b	-	20	-	10	230	4	7 <sup>a</sup>	90	3
b	-	10	-	20	230	4	9 <sup>a</sup>	26	65
c	-	-	10	10	120	5.5	100	-	-
c	-	-	10	10	230	4	-	100	-

<sup>a</sup>Compound **2b** is obtained together with a small amount of 1-(1-adamantyl)-5-methylpyrazole (4%)

The <sup>1</sup>H and <sup>13</sup>C NMR spectra of these compounds have been recorded in CDCl<sub>3</sub>. The steric hindrance of compound **4c** is apparent in the <sup>13</sup>C chemical shift of the 5-methyl group: compare 1,3,5-trimethylpyrazole (3-Me at 14.0 ppm, 5-Me at 11.7 ppm),<sup>13</sup> 1-(1-adamantyl)-3,5-dimethylpyrazole (3-Me at 13.3 ppm, 5-Me at 14.3 ppm)<sup>13</sup> and 1,4-di(1-adamantyl)-3,5-dimethylpyrazole **4c** (3-Me at 15.5 ppm, 5-Me at 17.1 ppm). In conclusion, we propose a new method of preparation of very congested heterocycles, a subject of several recent papers.<sup>14,15</sup>

#### References and Notes

- Cabildo, P.; Claramunt, R. M.; Elguero, J., *J. Heterocycl. Chem.*, **1984**, *21*, 249-251.
  - Cabildo, P.; Claramunt, R. M.; Sanz, D.; Foces-Foces, M. C.; Hernández-Cano, F.; Catalan, J.; Elguero, J. *Tetrahedron*, **1985**, *41*, 473-478.
  - González, M. E.; Alarcon, B.; Cabildo, P.; Claramunt, R. M.; Sanz, D.; Elguero, J.; *Eur. J. Med.-Chim. Ther.*, **1985**, *20*, 359-362.
  - Claramunt, R. M.; Cabildo, P.; Sanz, D.; Elguero, J.; *Spectros. Int. J.*, **1985**, *4*, 109-114.
  - Cabildo, P.; Claramunt, R. M.; Sanz, D.; Foces-Foces, M. C.; Hernández-Cano, F.; Fayet, J. P.; Vertut, M. C.; Elguero, J., *J. Heterocycl. Chem.*, **1986**, *23*, 1045-1050.
  - Sanz, D.; Terán, A.; Giraldez, A.; Birch, C.; Claramunt, R.M., *Farmacia Clínica*, **1987**, *4*, 711-720.
  - Claramunt, R. M.; Sanz, D.; Elguero, J.; Alvarez-Builla, J.; Gago, F.; *Il Farmaco- Ed. Sc.*, **1987**, *42*, 915-919.
  - Sanz, D.; Claramunt, R. M.; Elguero, J.; *S.T.P. PHARMA*, **1987**, *3*, 552-555.
  - Reichardt, C.; Würthwein, E.-U., *Z. Naturforsch.*, **1982**, *37b*, 1187-1195.
  - González, A.; Marquet, J.; Moreno-Mañas, M., *Tetrahedron*, **1986**, *42*, 4253-4257.
  - Trofimenko, S., personal communication.
  - The *typical procedure* is as follows: A mixture of the N-unsubstituted pyrazole **1** and 1-bromoadamantane in the proportions stated in Table 1 in a high pressure stainless steel autoclave of 250 ml (maximum working pressure of 200 atm), was heated in an oven during the appropriate reaction time. Once the heating was finished, we allowed the reactor to reach the room temperature and then the autoclave was opened and the reaction crude taken with 5ml of ethanol and 500ml of water. The acidic solution was neutralized with 1N NaOH. A precipitate was formed, filtered, dried and column chromatographed on silica gel Merck 60 (230-400 mesh) with CH<sub>2</sub>Cl<sub>2</sub> or CH<sub>2</sub>Cl<sub>2</sub>/EtOH as eluents. *Isolated yields (%)*: **2a**, 61; **2b**, 70; **2c**, 72; **3a**, 78; **3b**, 79; **3c**, 75; **4a**, 32; **4b**, 23; and **4c**, 19.
  - Begtrup, M.; Boyer, G.; Cabildo, P.; Cativiela, C.; Claramunt, R.M.; Elguero, J.; García, J.I.; Toiron, C.; Vedsø, P. *Magn. Reson. Chem.*, **1993**, *31*, 107-168.
  - Nakayama, J.; Hasemi, R. *J. Am. Chem. Soc.*, **1990**, *112*, 5654-5655.
  - Krebs, A.W.; Franken, E.; Müller, M.; Colberg, H.; Colcha, W.; Wilken, J.; Ohrenberg, J.; Albrecht, R.; Weiss, E. *Tetrahedron Lett.*, **1992**, *33*, 5947-5950
- We thank DGICYT of Spain for financial support (PB-90-0226-C02-02). One of us (I.F.) is indebted to the Ministère de la Recherche et de la Technologie of France for a postdoctoral fellowship.